Gallax Achieves Success in 8 out of 9 Cases in AI Antibody Design Comparison, Outperforming Competitors with 4-5 Cases
Comparison with Nabla Bio and Chai Discovery's Published Studies Using Common Targets
"Proving AI's Competitiveness in Designing Antibodies from Scratch"
Gallax, an artificial intelligence (AI) drug development company, announced on May 19 that its proprietary AI protein design platform, "Gallax Design," outperformed competitors in a global comparison of de novo antibody design technologies.
De novo antibody design is a technology in which AI designs entirely new antibodies capable of binding to specific proteins, rather than identifying existing antibodies. It is considered a next-generation technology that can accelerate the discovery of new drug candidates.
This study was conducted based on nine protein targets that could be commonly validated in recently published global de novo antibody design studies. The comparison included JAM-2 from Nabla Bio in the United States and Chai-2 from Chai Discovery.
Gallax explained that it designed 50 antibody candidates for each target and experimentally verified that it secured antibodies binding to the actual targets in eight out of the nine cases. Under the same criteria, Nabla Bio secured binding antibodies for five targets, and Chai Discovery for four targets.
The company emphasized that these results not only represent a higher number of successes, but also demonstrate the capability to consistently design antibodies across a diverse range of targets. Until now, each company had announced results based on different conditions and targets, making direct comparisons difficult. This study, however, compared performance using common targets.
However, the company noted that producing antibodies that bind to a target does not immediately lead to the development of a therapeutic drug. For a candidate to become an actual new drug, further validation of safety, efficacy, and manufacturability is required. Nevertheless, the company assessed that these results are meaningful in that they can significantly accelerate the early discovery of candidates.
Gallax also previously announced last year that its AI-designed antibody candidates achieved a binding success rate of over 30% across eight different target sites.
Tae-yong Park, Vice President of Gallax, said, "AI antibody design technology is advancing beyond simple proof-of-concept toward reliably generating desired antibodies for a wide range of targets," adding, "This will greatly accelerate the pace of early candidate discovery."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In a comparison based on 9 common targets, Galaxy Design succeeded in obtaining bispecific antibodies for 8 targets, showing the highest target-specific success rate compared to JAM-2 with 5 targets and Chai-2 with 4 targets. Galaxy
View original image© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.